Recent Research Funding

Faculty secure several million dollars annually for their research from various public and private sources, including the National Institutes of Health, U.S. Food and Drug Administration, National Multiple Sclerosis Society, foundations and pharmaceutical firms.

  • A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis, BEAT-MS (Protocol ITN077AI). Bianca Weinstock-Guttman (Principal Investigator). National Institute of Allergy & Infectious Diseases (NIAID), Division of Allergy, Immunology &Transplantation (DAIT) via a subaward. 1/1/2020-12/1/2026.
  • Clinical, Genetic, and Cellular Consequences of Mutations in Na, K-ATP1A3. Allison Brashear (Principal Investigator). NINDS. $8,808,869. 4/1/2008-6/1/2026.
  • Optimizing Chest Compressions Targeting Gas Exchange and Hemodynamics in a Transitional Cardiac Arrest Model. Ferdinand Schweser (Co-Investigator). National Institutes of Health. $1,642,389. 4/1/2021-3/1/2026.
  • A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063). Bianca Weinstock-Guttman (Principal Investigator). Celgene International. 6/1/2020-12/1/2025.
  • Neural indices of cognitive decline and cognitive resiliency in people with neurological disturbances. Thomas Covey (Principal Investigator). National Institutes of Health. $28,321. 10/1/2023-10/1/2025.
  • Deep gray matter iron and disease progression in multiple sclerosis. Ferdinand Schweser (Principal Investigator). National Institutes of Health. $1,808,000. 7/1/2021-6/1/2025.
  • Feasibility of the Multiple Sclerosis Performance Test for assessment of functional performance measures in patients with Multiple Sclerosis (US-MSG-18-11424). Bianca Weinstock-Guttman (Principal Investigator). Biogen. 6/1/2019-12/1/2024.
  • Buffalo Clinical and Translational Research Center. Ferdinand Schweser (Co-Investigator). National Institutes of Health. $19,101,902. 2/1/2020-12/1/2024.
  • Investigation of behavioral and neural indices of multisensory information processing in Multiple Sclerosis: A novel approach. Thomas Covey (Principal Investigator). Department of Defense Multiple Sclerosis Research Program. $232,022. 9/1/2021-9/1/2024.
  • Buffalo Clinical and Translational Research Center. Kinga Szigeti (Co-Investigator). NIH/NCATS. 7/1/2019-7/1/2024.
  • Phase 3 randomized, double blind, placebo-controlled multicenter study to evaluate satralizumab in generalized myasthenia gravis (LUMINESCE). Gil Wolfe (Co-Investigator). Roche. 1/1/2021-3/1/2024.
  • Investigation of behavioral and neural indices of multisensory information processing in Multiple Sclerosis: A novel approach. Exploration -hypothesis development award. David Shucard (Co-Investigator). Department of Defense Multiple Sclerosis Research Program. $232,022. 10/1/2021-10/1/2023.
  • A novel method for the investigation of the neural underpinnings of performance on the Symbol Digit Modalities Test in Multiple Sclerosis (Pilot Research Grant). David Shucard (Co-Investigator). National Multiple Sclerosis Society. $55,000. 10/1/2021-10/1/2023.
  • A novel method for the investigation of the neural underpinnings of performance on the Symbol Digit Modalities Test in Multiple Sclerosis. Thomas Covey (Principal Investigator). National Multiple Sclerosis Society. $55,000. 10/1/2020-9/1/2023.
  • Investigation of novel neural indices of cognitive decline and methods for cognitive rehabilitation in people with neurological disturbances. Thomas Covey (Principal Investigator). National Institutes of Health Loan Repayment Program Award. $38,343. 9/1/2021-9/1/2023.
  • Advanced hybrid PET-MRI imaging pipeline at 9.4T. Ferdinand Schweser (Principal Investigator). University at Buffalo. $100,000. 8/1/2021-7/1/2023.
  • Advanced hybrid PET-MRI imaging pipeline at 9.4T. Ferdinand Schweser (Principal Investigator). 8/1/2021-7/1/2023.
  • Network of Excellence in Neuroscience Clinical Trial: NeuroNEXT. Gil Wolfe (Principal Investigator). NIH/NINDS. $250,000. 7/1/2018-6/1/2023.
  • Supporting an aging workforce in future transportation and delivery work. Thomas Covey (Co-Principal Investigator). National Science Foundation. $149,580. 10/1/2020-9/1/2022.
  • Neonatal Research Network. Osman Farooq (Co-Investigator), Michelle Hartley-McAndrew (Co-Investigator). Eunice Kennedy Shriver National Institute of Child Health and Human Development. 4/1/2011-8/1/2022.